Many infections of SARS-CoV-2 (novel coronavirus) will likely go undetected, because of lack of access to testing and the lack of symptoms amongst many individuals infected .
Estimated total and diagnosed total cases in 2020
As of March 23rd, over 15,000 fatalities due to COVID-19 have been confirmed  . Preliminary research has yielded case fatality rate numbers between 2% and 3% . in January 2020 the WHO suggested that the case fatality rate was approximately 3% .
Predicted total number of fatalities worldwide
It is currently not known when the global coronavirus outbreak will peak, as this depends on country-based mitigation efforts, medical advances, and a series of key epidemiological factors, some of which are poorly understood at present for COVID-19 .
Predicted total diagnosed cases globally across various quarters
Six territories (Western Pacific Region, European Region, South-East Asia Region, Eastern Mediterranean Region, Region of the Americas, African Region) have reported cases of COVID19 . The level of risk of local spread varies between regions. Some regions are currently only experiencing imported cases, whereas in others local transmission is occurring . Mitigation responses also vary regionally.
Total cumulative diagnosed infections across WHO regions
Total cumulative diagnosed infections across the US, UK, Europe and the location with the highest number of cases outside of mainland China
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine. In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months .
Predicted timeline for a vaccine being administered outside of clinical trials
Remdesivir is a novel antiviral drug in the class of nucleotide analogs. It was developed by Gilead Sciences and as a treatment for Ebola virus disease and Marburg virus infections . Remdesivir has been administered to several hundred patients with confirmed, severe SARS-CoV-2 infections in the United States, Europe, and Japan through Expanded Access or Compassionate Use programs . On 20 March 2020, the FDA made remdesivir available for compassionate use to patients who have tested positive for COVID-19 .
The proportion of deaths to the total numbers of cases, or case fatality rate (CFR). The CFR is not a value which is tied to the given disease, but is instead reflective of the severity of the disease in a particular context, at a particular time, in a particular population .